Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.

Autor:	Thompson J; Department of Internal Medicine, University of Cincinnati Medical Center, University of Cincinnati, 51 Goodman Drive, Cincinnati, OH 45267, USA., Schacht S; Department of Internal Medicine, University of Cincinnati Medical Center, University of Cincinnati, 51 Goodman Drive, Cincinnati, OH 45267, USA., Rothenberg F; Department of Internal Medicine, University of Cincinnati Medical Center, University of Cincinnati, 51 Goodman Drive, Cincinnati, OH 45267, USA; University of Cincinnati, VAMC Cincinnati, 3200 Vine Street, Cincinnati, OH 45267, USA. Electronic address: florence.rothenberg@uc.edu.
Jazyk:	angličtina
Zdroj:	Cardiology clinics [Cardiol Clin] 2019 Aug; Vol. 37 (3), pp. 335-343. Date of Electronic Publication: 2019 May 08.
DOI:	10.1016/j.ccl.2019.04.007
Abstrakt:	Diabetes is a major risk factor for cardiovascular disease, yet until now treatments for diabetes had only a modest impact on cardiovascular events. New interventions for patients with type 2 diabetes mellitus (oral empagliflozin and injectable liraglutide) are associated with unprecedented reductions in composite cardiovascular outcomes that seem disproportionate to the impact on glycated hemoglobin. This review examines in detail the recent trials that arrived at these conclusions, limitations of these studies, and how these outcomes may influence patient management in the future. (Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu